Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

SVP, CFO

President and CEO

EVP, COO

SVP, GC, BD & Corp Affairs

SVP, GC and Corporate Affairs

SVP and CFO

SVP Operations, CMO

Board of Directors

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of ...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-04	Premium	acquired	Premium	Premium	Premium	SVP, CFO
2024-03-03	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-03-03	Premium	acquired	Premium	Premium	Premium	EVP, COO
2024-03-03	Premium	acquired	Premium	Premium	Premium	SVP, GC, BD & Corp Affairs
2024-03-02	Premium	acquired	Premium	Premium	Premium	SVP, CFO
2024-03-02	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-03-02	Premium	acquired	Premium	Premium	Premium	EVP, COO
2024-03-02	Premium	acquired	Premium	Premium	Premium	SVP, GC, BD & Corp Affairs
2024-01-29	Premium	acquired	Premium	Premium	Premium	SVP, CFO
2024-01-28	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-01-28	Premium	acquired	Premium	Premium	Premium	EVP, COO
2023-08-09	Premium	acquired	Premium	Premium	Premium	-
2023-08-09	Premium	acquired	Premium	Premium	Premium	-
2023-08-09	Premium	acquired	Premium	Premium	Premium	-
2023-08-09	Premium	acquired	Premium	Premium	Premium	-
2023-08-09	Premium	acquired	Premium	Premium	Premium	-
2023-08-08	Premium	acquired	Premium	Premium	Premium	SVP, GC, BD & Corp Affairs
2023-08-08	Premium	acquired	Premium	Premium	Premium	SVP, CFO
2023-08-08	Premium	acquired	Premium	Premium	Premium	EVP, COO
2023-06-01	Premium	acquired	Premium	Premium	Premium	-
2023-06-01	Premium	acquired	Premium	Premium	Premium	-
2023-06-01	Premium	acquired	Premium	Premium	Premium	-
2023-06-01	Premium	acquired	Premium	Premium	Premium	-
2023-06-01	Premium	acquired	Premium	Premium	Premium	-
2023-05-31	Premium	acquired	Premium	Premium	Premium	SVP, GC, BD & Corp Affairs

APVO - Aptevo Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for APVO